The Center for Advancing Point of Care in Heart, Lung, Blood and Sleep Diseases

心脏、肺、血液和睡眠疾病护理点推进中心

• 批准号: 10735580
• 负责人: BRYAN O BUCHHOLZ
• 金额: $ 181.84万
• 依托单位: UNIV OF MASSACHUSETTS MED SCH WORCESTER
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-08-22 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10735580
• 关键词: Acceleration; Address; Adoption; Advisory Committees; Affect; American; Automobile Driving; Blood; Businesses; COVID-19 pandemic; COVID-19 testing; Cardiovascular system; Caregivers; Caring; Cessation of life; Client satisfaction; Clinic; Clinical; Clinical Research; Communication; Community Health; Data; Decision Making; Development; Device or Instrument Development; Diagnosis; Disease; Disparity; Engineering; Environment; Equitable healthcare; Family; Funding; Goals; Grant; Health; Health Personnel; Health Professional; Health Promotion; Health system; Healthcare; Heart; Heart Diseases; Hematological Disease; Home; Income; Incubated; Incubators; Intellectual Property; Knowledge; Legal patent; Life; Lung; Lung diseases; Marketing; Massachusetts; Medical; Medical Device; Mentors; Methodology; Modeling; Morbidity - disease rate; Needs Assessment; Outcome; Pathway interactions; Patients; Point of Care Technology; Policy Maker; Population Heterogeneity; Prevention; Process; Provider; Quality of Care; Research; Research Personnel; Resource-limited setting; Resources; Risk; Running; Sleep; Sleep Disorders; System; Technology; Telemedicine; Therapeutic; Time; Training; Underserved Population; United States National Institutes of Health; Universities; Vision; Work; acute care; clinical development; commercialization; community engagement; cost; design; evidence base; experience; health care availability; health care quality; health equity; health management; home test; improved; industry partner; innovation; marginalized population; medical schools; mortality; new technology; novel; patient engagement; patient oriented; personalized management; point of care; prevent; programs; research clinical testing; success; technology research and development; tool; trend; trial design; virtual healthcare

Project Summary/Abstract – Overall Core American healthcare is rapidly evolving to a state where efficiency, quality and patient satisfaction are dominant drivers. Several trends are driving fundamental changes in health care: 1) an expanding scope of virtual care and telemedicine, accelerated by the COVID-19 pandemic, has changed how patients, healthcare providers, and health systems interact; 2) a growing recognition of disparities leading to an emphasis in providing healthcare equitably for historically marginalized populations; 3) an increasing appreciation for the patient as a critical stakeholder in therapeutic decision-making, leading to an emphasis on patient-centered design; and 4) increasing access to home health to enable better diagnosis, prevention and management of health conditions, as illustrated by widespread adoption of home-testing for SARS-CoV-2. Despite this rapidly changing environment, heart (cardiovascular), lung, blood, and sleep disorders (HLBS) continue to cause significant morbidity, mortality, and cost in the US and worldwide. Combined, these diseases account for 41% of deaths in the US and lead to over $400B in direct health care expenses plus lost income to affected patients and caregivers. Thus, there are urgent unmet needs in HLBS. We will address these issues with the renewal of the Center for Advancing Point of Care Technologies (CAPCaT) in HLBS Disorders. CAPCaT is a highly successful Point-of-Care Technology Research Network (POCTRN) Center that leverages our experience running a medical product incubator, the Massachusetts Medical Device Development Center (M2D2) at the University of Massachusetts (Lowell and Worcester campuses), and our experience administering grants, running, and managing solicitations, and working 1:1 with awardees to advance their technologies toward commercialization. CAPCaT expanded upon the original vision and success of M2D2 and now has its own established track record and collaborative network to develop and optimize novel POC and home-based technologies to improve the diagnosis and management of HLBS disorders. Our objectives in achieving this goal are to continue: 1) identifying, through stakeholder engagement, the most promising POC and home-based technologies to address unmet medical needs; 2) supporting developmental plans, including pathways to adoption at the point of care or in the home; and 3) training and disseminating developing POC and home-based technologies to the different stakeholders.

项目摘要/摘要-总体核心 美国的医疗保健正迅速演变为效率、质量和患者满意度占主导地位的状态 司机。几个趋势正在推动医疗保健的根本性变化：1)虚拟医疗服务的范围不断扩大 而远程医疗，由于新冠肺炎的流行而加速，已经改变了患者、医疗保健提供者、 和卫生系统相互作用；2)对差距的日益认识，导致对提供卫生保健的重视 对于历史上被边缘化的人群是公平的；3)对患者作为危重患者的认识越来越高 利益相关者参与治疗决策，导致强调以患者为中心的设计；以及4) 增加获得家庭保健的机会，以便能够更好地诊断、预防和管理健康状况； SARS-CoV-2病毒的家庭检测被广泛采用就是例证。尽管这种变化很快 环境、心脏(心血管)、肺、血液和睡眠障碍(HLBS)继续引起重大 美国和全世界的发病率、死亡率和成本。这些疾病加在一起，占#年死亡人数的41% 并导致超过4000亿美元的直接医疗费用，加上受影响患者和 照顾者。因此，HLBS存在着迫切的未得到满足的需求。我们将通过更新 HLBS疾病的先进护理技术中心(CAPCaT)。CAPCaT是一项非常成功的 医疗保健技术研究网络(POCTRN)中心，利用我们的运营经验 医疗产品孵化器，马萨诸塞州大学医疗器械开发中心(M2D2) 马萨诸塞州(洛厄尔和伍斯特校区)，以及我们管理拨款、运行和 管理征集，并与获奖者1：1合作，推动他们的技术走向商业化。 CAPCaT在M2D2最初的愿景和成功的基础上进行了扩展，现在已经有了自己的记录 和协作网络，以开发和优化新的PoC和基于家庭的技术，以提高 HLBS疾病的诊断和治疗。我们实现这一目标的目标是继续：1) 通过利益相关者的参与，确定最有前景的概念验证和基于家庭的技术 未得到满足的医疗需求；2)支持发展计划，包括在护理或护理时采用的途径 在家中；以及3)培训和传播开发PoC和基于家庭的技术给不同的 利益相关者。

项目成果

Respiratory Adenovirus Quantification with a Droplet Digital Polymerase Chain Reaction (ddPCR) Assay.

使用微滴数字聚合酶链式反应 (ddPCR) 测定进行呼吸道腺病毒定量。

• DOI: 10.1128/spectrum.00269-23
• 发表时间: 2023-06-15
• 期刊: Microbiology spectrum
• 影响因子: 3.7

Dynamic pH and Thermal Analysis of Paper-Based Microchip Electrophoresis.

• DOI: 10.3390/mi12111433
• 发表时间: 2021-11-22
• 期刊: Micromachines
• 影响因子: 3.4
• 作者: Hasan MN;An R;Akkus A;Akkaynak D;Minerick AR;Kharangate CR;Gurkan UA
• 通讯作者: Gurkan UA

Increased circulation of human adenovirus in 2023: an investigation of the circulating genotypes, upper respiratory viral loads, and hospital admissions in a large academic medical center.

• DOI: 10.1128/jcm.01237-23
• 发表时间: 2024-01-17
• 期刊: Journal of clinical microbiology
• 影响因子: 9.4

N-protein presents early in blood, dried blood and saliva during asymptomatic and symptomatic SARS-CoV-2 infection.

• DOI: 10.1038/s41467-021-22072-9
• 发表时间: 2021-03-26
• 期刊: Nature communications
• 影响因子: 16.6
• 作者: Shan D;Johnson JM;Fernandes SC;Suib H;Hwang S;Wuelfing D;Mendes M;Holdridge M;Burke EM;Beauregard K;Zhang Y;Cleary M;Xu S;Yao X;Patel PP;Plavina T;Wilson DH;Chang L;Kaiser KM;Nattermann J;Schmidt SV;Latz E;Hrusovsky K;Mattoon D;Ball AJ
• 通讯作者: Ball AJ

Actigraphy: Metrics reveal it is not a valid tool for determining sleep in neonates.

• DOI: 10.1111/jsr.13444
• 发表时间: 2022-02
• 期刊: JOURNAL OF SLEEP RESEARCH
• 影响因子: 4.4
• 作者: Derbin, Matthew;McKenna, Lauren;Chin, Donald;Coffman, Brian;Bloch-Salisbury, Elisabeth
• 通讯作者: Bloch-Salisbury, Elisabeth